Latest Financials News

Platinum Asia Investments Limited (PAI) held a pivotal Scheme Meeting seeking shareholder approval to restructure by exchanging shares for units in the Platinum Asia Fund Complex ETF (PAXX), accompanied by a special dividend payment. The outcome will reshape PAI’s investment management and ownership structure.

Platinum Asia Investments Limited has announced a special dividend of AUD 0.1992 per share, pending court approval and final confirmation post-scheme valuation. The payment is scheduled for September 2025 with a significant franked component.

Resouro Strategic Metals reports a significant update to its Tiros project resource alongside a reduced quarterly loss, highlighting progress in its Brazilian exploration assets.

Kelly Partners Group Holdings posted a robust 24.5% revenue increase to $134.6 million in FY25, driven by strategic international expansions and acquisitions. The firm’s underlying profit after tax also rose 13%, underscoring its growing footprint across Australia, the US, and Ireland.

LGI Limited reported a robust FY25 with 14% EBITDA growth driven by expanded renewable energy capacity and carbon credit sales, while setting ambitious FY26 guidance of 25-30% EBITDA growth.

Anteris Technologies reported solid clinical progress with 130 patients implanted with its DurAVR heart valve and is gearing up for its pivotal PARADIGM trial with 79 qualified sites worldwide. The company also strengthened its leadership with two new board members amid ongoing FDA engagement.

LGI Limited reported a 14% rise in FY25 EBITDA to $17.4 million, driven by operational growth and expanded renewable capacity. The company also secured a landmark 15-year contract to build and operate a 12MW/24MWh battery system at the Belrose landfill site in NSW.

LGI Limited reported a robust FY25 with a 13.6% increase in underlying EBITDA to $17.4 million, expanded renewable capacity by 44%, and declared a fully franked dividend. The company’s strategic investments in battery storage and biogas infrastructure position it well in Australia’s energy transition.

Anteris Technologies Global Corp. reported a $42.7 million net loss for the first half of 2025 amid advancing preparations for its pivotal DurAVR Transcatheter Heart Valve trial. The company’s recent IPO proceeds are fueling R&D and manufacturing scale-up as it targets regulatory approvals.

Tryptamine Therapeutics has locked in $2.6 million in non-dilutive funding to fast-track clinical trials of its lead psilocin-based therapy, TRP-8803, targeting binge eating disorder and other conditions.

Iondrive Limited has won a $3.9 million government grant to advance its innovative urban mining technology, accelerating the construction of a pilot plant focused on critical minerals recovery from lithium-ion batteries.

AJ Lucas Group’s UK arm Cuadrilla Resources has settled a long-standing dispute over shale gas licences, receiving £12.5 million and terminating the carry agreement. This resolution clears a financial uncertainty clouding the company’s UK operations.